This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Northport, Virginia 11768, United States
Hyderabaad, Hyderabad 500 036, India
Selangor Darul Ehsan, Ehsan, Malaysia
Kuala Lumpur, Selangor, Malaysia
Selangor Darul Ehsan, Selangor, Malaysia
Komarnanska, Velky Meder 932 01, Slovakia